It's How Medicine Should Be®

Physician Profile

-or-

call (888) 352-RUSH for help arranging an appointment

Jochen Reiser, MD, PhD

Specialty:
  • Nephrology
  • Internal Medicine
Board Certification:
  • Internal Medicine
Faculty Rank: Professor
Medical or Graduate Education: University of Heidelberg Medical Faculty, Germany
Residency: Montefiore Medical Center - Internal Medicine
Fellowship: Harvard Medical School - Nephrology
Clinical Expertise:
  • Diabetes
  • Glomerulonephritis
  • Kidney disease
  • Nephrotic syndrome
  • Proteinuria
  • Vasculitis
Research Interests:
  • Focal segmental glomerulosclerosis (FSGS)
  • Proteolytic and enzymatic regulation of podocyte function
  • Kidney and organ regeneration and repair
  • Molecular basis of human diseases
  • Post-transplant organ disease
Languages Spoken:
  • French
  • German
Google Map

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to PubMed.gov). Listings go back five years.

  1. Podocyte-associated talin1 is critical for glomerular filtration barrier maintenance.
    Tian X, Kim JJ, Monkley SM, Gotoh N, Nandez R, Soda K, Inoue K, Balkin DM, Hassan H, Son SH, Lee Y, Moeckel G, Calderwood DA, Holzman LB, Critchley DR, Zent R, Reiser J, Ishibe S
    J. Clin. Invest.
    2014 Mar 3
    124(3):1098-113.
  2. Abatacept in B7-1-positive proteinuric kidney disease.
    Alachkar N, Carter-Monroe N, Reiser J
    N. Engl. J. Med.
    2014 Mar 27
    370(13):1263-4.
  3. Proteinuria: abate or applaud abatacept in proteinuric kidney disease?
    Reiser J, Alachkar N
    Nat Rev Nephrol
    2014 Mar
    10(3):128-30.
  4. Reduction of Proteinuria through Podocyte Alkalinization.
    Altintas MM, Moriwaki K, Wei C, Möller CC, Flesche J, Li J, Yaddanapudi S, Faridi MH, Gödel M, Huber TB, Preston RA, Jiang JX, Kerjaschki D, Sever S, Reiser J
    J. Biol. Chem.
    2014 Jun 20
    289(25):17454-67.
  5. Sphingomyelinase-Like Phosphodiesterase 3b Expression Levels Determine Podocyte Injury Phenotypes in Glomerular Disease.
    Yoo TH, Pedigo CE, Guzman J, Correa-Medina M, Wei C, Villarreal R, Mitrofanova A, Leclercq F, Faul C, Li J, Kretzler M, Nelson RG, Lehto M, Forsblom C, Groop PH, Reiser J, Burke GW, Fornoni A, Merscher S
    J. Am. Soc. Nephrol.
    2014 Jun 12
  6. Role of podocyte b7-1 in diabetic nephropathy.
    Fiorina P, Vergani A, Bassi R, Niewczas MA, Altintas MM, Pezzolesi MG, D'Addio F, Chin M, Tezza S, Ben Nasr M, Mattinzoli D, Ikehata M, Corradi D, Schumacher V, Buvall L, Yu CC, Chang JM, La Rosa S, Finzi G, Solini A, Vincenti F, Rastaldi MP, Reiser J, Krolewski AS, Mundel PH, Sayegh MH
    J. Am. Soc. Nephrol.
    2014 Jul
    25(7):1415-29.
  7. Structure of the Kidney Slit Diaphragm Adapter Protein CD2-Associated Protein as Determined with Electron Microscopy.
    Adair BD, Altintas MM, Möller CC, Arnaout MA, Reiser J
    J. Am. Soc. Nephrol.
    2014 Jul
    25(7):1465-73.
  8. Signal transduction in podocytes-spotlight on receptor tyrosine kinases.
    Reiser J, Sever S, Faul C
    Nat Rev Nephrol
    2014 Feb
    10(2):104-15.
  9. Soluble Urokinase-Type Plasminogen Activator Receptor in FSGS: Stirred but Not Shaken.
    Reiser J, Chapman H
    J. Am. Soc. Nephrol.
    2014 Aug
    25(8):1611-3.
  10. CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance: Response.
    Cara-Fuentes G, Johnson RJ, Reiser J, Garin EH
    Pediatr. Nephrol.
    2014 Aug
    29(8):1467-8.
  11. CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance.
    Cara-Fuentes G, Wei C, Segarra A, Ishimoto T, Rivard C, Johnson RJ, Reiser J, Garin EH
    Pediatr. Nephrol.
    2014 Aug
    29(8):1363-71.
  12. MicroRNA-29a Promotion of Nephrin Acetylation Ameliorates Hyperglycemia-Induced Podocyte Dysfunction.
    Lin CL, Lee PH, Hsu YC, Lei CC, Ko JY, Chuang PC, Huang YT, Wang SY, Wu SL, Chen YS, Chiang WC, Reiser J, Wang FS
    J. Am. Soc. Nephrol.
    2014 Aug
    25(8):1698-709.
  13. An Interferon-Induced Digital Vasculitis-Like Syndrome: A Case Report.
    Hamidi O, Reiser J, Hasler S
    Am J Ther
    2014 Apr 11
  14. Rituximab: a boot to protect the foot.
    Reiser J, Fornoni A
    J. Am. Soc. Nephrol.
    2014 Apr
    25(4):647-8.
  15. In vivo imaging of kidney glomeruli transplanted into the anterior chamber of the mouse eye.
    Kistler AD, Caicedo A, Abdulreda MH, Faul C, Kerjaschki D, Berggren PO, Reiser J, Fornoni A
    Sci Rep
    2014
    4:3872.
  16. Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy.
    Alachkar N, Wei C, Arend LJ, Jackson AM, Racusen LC, Fornoni A, Burke G, Rabb H, Kakkad K, Reiser J, Estrella MM
    Transplantation
    2013 Oct 15
    96(7):649-56.
  17. Akt2 relaxes podocytes in chronic kidney disease.
    Reiser J
    Nat. Med.
    2013 Oct
    19(10):1212-3.
  18. Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome.
    Ravani P, Ponticelli A, Siciliano C, Fornoni A, Magnasco A, Sica F, Bodria M, Caridi G, Wei C, Belingheri M, Ghio L, Merscher-Gomez S, Edefonti A, Pasini A, Montini G, Murtas C, Wang X, Muruve D, Vaglio A, Martorana D, Pani A, Scolari F, Reiser J, Ghiggeri GM
    Kidney Int.
    2013 Nov
    84(5):1025-33.
  19. Management of severe recurrent focal segmental glomerulosclerosis through circulating soluble urokinase receptor modification.
    Morath C, Wei C, Macher-Goeppinger S, Schwenger V, Zeier M, Reiser J
    Am J Ther
    2013 Mar-Apr
    20(2):226-9.
  20. Circulating factor in FSGS: a black sheep in the suPAR family?
    Trachtman H, Wei C, Reiser J
    Pediatr. Nephrol.
    2013 Jul
    28(7):1151-2.
  21. Transmission of glomerular permeability factor soluble urokinase plasminogen activator receptor (suPAR) from a mother to child.
    Kemper MJ, Wei C, Reiser J
    Am. J. Kidney Dis.
    2013 Feb
    61(2):352.
  22. Transient receptor potential channel 6 (TRPC6) protects podocytes during complement-mediated glomerular disease.
    Kistler AD, Singh G, Altintas MM, Yu H, Fernandez IC, Gu C, Wilson C, Srivastava SK, Dietrich A, Walz K, Kerjaschki D, Ruiz P, Dryer S, Sever S, Dinda AK, Faul C, Reiser J
    J. Biol. Chem.
    2013 Dec 20
    288(51):36598-609.
  23. Is there clinical value in measuring suPAR levels in FSGS?
    Sever S, Trachtman H, Wei C, Reiser J
    Clin J Am Soc Nephrol
    2013 Aug
    8(8):1273-5.
  24. C-kit(+) cells isolated from developing kidneys are a novel population of stem cells with regenerative potential.
    Rangel EB, Gomes SA, Dulce RA, Premer C, Rodrigues CO, Kanashiro-Takeuchi RM, Oskouei B, Carvalho DA, Ruiz P, Reiser J, Hare JM
    Stem Cells
    2013 Aug
    31(8):1644-56.
  25. Circulating permeability factor suPAR: from concept to discovery to clinic.
    Reiser J
    Trans. Am. Clin. Climatol. Assoc.
    2013
    124:133-8.
  26. CD80, suPAR and nephrotic syndrome in a case of NPHS2 mutation.
    Cara-Fuentes G, Araya C, Wei C, Rivard C, Ishimoto T, Reiser J, Johnson RJ, Garin EH
    Nefrologia
    2013
    33(5):727-31.
  27. Cellular effects of everolimus and sirolimus on podocytes.
    Müller-Krebs S, Weber L, Tsobaneli J, Kihm LP, Reiser J, Zeier M, Schwenger V
    PLoS ONE
    2013
    8(11):e80340.
  28. Podocyte biology and pathogenesis of kidney disease.
    Reiser J, Sever S
    Annu. Rev. Med.
    2013
    64:357-66.
  29. Is podocyte research at a tipping point? Report from the 9(th) International Podocyte Conference.
    Schell CB, Kerjaschki D, Reiser J, Huber TB
    Kidney Int.
    2012 Nov
    82(10):1041-3.
  30. Podocyte foot process effacement in postreperfusion allograft biopsies correlates with early recurrence of proteinuria in focal segmental glomerulosclerosis.
    Chang JW, Pardo V, Sageshima J, Chen L, Tsai HL, Reiser J, Wei C, Ciancio G, Burke GW, Fornoni A
    Transplantation
    2012 Jun 27
    93(12):1238-44.
  31. Podocyte GTPases regulate kidney filter dynamics.
    Kistler AD, Altintas MM, Reiser J
    Kidney Int.
    2012 Jun
    81(11):1053-5.
  32. Soluble urokinase receptor and focal segmental glomerulosclerosis.
    Reiser J, Wei C, Tumlin J
    Curr. Opin. Nephrol. Hypertens.
    2012 Jul
    21(4):428-32.
  33. Cytoprotective signaling by activated protein C requires protease-activated receptor-3 in podocytes.
    Madhusudhan T, Wang H, Straub BK, Gröne E, Zhou Q, Shahzad K, Müller-Krebs S, Schwenger V, Gerlitz B, Grinnell BW, Griffin JH, Reiser J, Gröne HJ, Esmon CT, Nawroth PP, Isermann B
    Blood
    2012 Jan 19
    119(3):874-83.
  34. The calcineurin-NFAT pathway allows for urokinase receptor-mediated beta3 integrin signaling to cause podocyte injury.
    Zhang B, Shi W, Ma J, Sloan A, Faul C, Wei C, Reiser J, Yang Y, Liu S, Wang W
    J. Mol. Med.
    2012 Dec
    90(12):1407-20.
  35. Expression of fgf23 and aklotho in developing embryonic tissues and adult kidney of the zebrafish, Danio rerio.
    Mangos S, Amaral AP, Faul C, Jüppner H, Reiser J, Wolf M
    Nephrol. Dial. Transplant.
    2012 Dec
    27(12):4314-22.
  36. Circulating suPAR in two cohorts of primary FSGS.
    Wei C, Trachtman H, Li J, Dong C, Friedman AL, Gassman JJ, McMahan JL, Radeva M, Heil KM, Trautmann A, Anarat A, Emre S, Ghiggeri GM, Ozaltin F, Haffner D, Gipson DS, Kaskel F, Fischer DC, Schaefer F, Reiser J,
    J. Am. Soc. Nephrol.
    2012 Dec
    23(12):2051-9.
  37. Regarding Maas's editorial letter on serum suPAR levels.
    Trachtman H, Gipson DS, Kaskel F, Ghiggeri GM, Faul C, Gupta V, Fornoni A, Burke GW, Thomas DB, Barisoni L, Schaefer F, Wei C, Reiser J
    Kidney Int.
    2012 Aug
    82(4):492.
  38. Human RAGE antibody protects against AGE-mediated podocyte dysfunction.
    Müller-Krebs S, Kihm LP, Madhusudhan T, Isermann B, Reiser J, Zeier M, Schwenger V
    Nephrol. Dial. Transplant.
    2012 Aug
    27(8):3129-36.
  39. Leptin deficiency-induced obesity affects the density of mast cells in abdominal fat depots and lymph nodes in mice.
    Altintas MM, Nayer B, Walford EC, Johnson KB, Gaidosh G, Reiser J, De La Cruz-Munoz N, Ortega LM, Nayer A
    Lipids Health Dis
    2012
    11:21.
  40. Small molecule-mediated activation of the integrin CD11b/CD18 reduces inflammatory disease.
    Maiguel D, Faridi MH, Wei C, Kuwano Y, Balla KM, Hernandez D, Barth CJ, Lugo G, Donnelly M, Nayer A, Moita LF, Schürer S, Traver D, Ruiz P, Vazquez-Padron RI, Ley K, Reiser J, Gupta V
    Sci Signal
    2011 Sep 6
    4(189):ra57.
  41. Pathogenic old world hantaviruses infect renal glomerular and tubular cells and induce disassembling of cell-to-cell contacts.
    Krautkrämer E, Grouls S, Stein N, Reiser J, Zeier M
    J. Virol.
    2011 Oct
    85(19):9811-23.
  42. Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway.
    Nijenhuis T, Sloan AJ, Hoenderop JG, Flesche J, van Goor H, Kistler AD, Bakker M, Bindels RJ, de Boer RA, Möller CC, Hamming I, Navis G, Wetzels JF, Berden JH, Reiser J, Faul C, van der Vlag J
    Am. J. Pathol.
    2011 Oct
    179(4):1719-32.
  43. CD2AP in mouse and human podocytes controls a proteolytic program that regulates cytoskeletal structure and cellular survival.
    Yaddanapudi S, Altintas MM, Kistler AD, Fernandez I, Möller CC, Wei C, Peev V, Flesche JB, Forst AL, Li J, Patrakka J, Xiao Z, Grahammer F, Schiffer M, Lohmüller T, Reinheckel T, Gu C, Huber TB, Ju W, Bitzer M, Rastaldi MP, Ruiz P, Tryggvason K, Shaw AS, Faul C, Sever S, Reiser J
    J. Clin. Invest.
    2011 Oct
    121(10):3965-80.
  44. In vivo electroporation and non-protein based screening assays to identify antibodies against native protein conformations.
    Daftarian P, Chowdhury R, Ames P, Wei C, King AD, de Rivero Vaccari JP, Dillon L, Price J, Leung H, Ashlock B, Mesri E, Perez V, Züchner S, Reiser J, Lemmon V, Keane RW
    Hybridoma (Larchmt)
    2011 Oct
    30(5):409-18.
  45. Fishing for new glomerular disease-related genes.
    Mangos S, Reiser J
    J. Am. Soc. Nephrol.
    2011 Nov
    22(11):1960-2.
  46. COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness.
    Heeringa SF, Chernin G, Chaki M, Zhou W, Sloan AJ, Ji Z, Xie LX, Salviati L, Hurd TW, Vega-Warner V, Killen PD, Raphael Y, Ashraf S, Ovunc B, Schoeb DS, McLaughlin HM, Airik R, Vlangos CN, Gbadegesin R, Hinkes B, Saisawat P, Trevisson E, Doimo M, Casarin A, Pertegato V, Giorgi G, Prokisch H, Rötig A, Nürnberg G, Becker C, Wang S, Ozaltin F, Topaloglu R, Bakkaloglu A, Bakkaloglu SA, Müller D, Beissert A, Mir S, Berdeli A, Varpizen S, Zenker M, Matejas V, Santos-Ocaña C, Navas P, Kusakabe T, Kispert A, Akman S, Soliman NA, Krick S, Mundel P, Reiser J, Nürnberg P, Clarke CF, Wiggins RC, Faul C, Hildebrandt F
    J. Clin. Invest.
    2011 May
    121(5):2013-24.
  47. Genome-wide studies of copy number variation and exome sequencing identify rare variants in BAG3 as a cause of dilated cardiomyopathy.
    Norton N, Li D, Rieder MJ, Siegfried JD, Rampersaud E, Züchner S, Mangos S, Gonzalez-Quintana J, Wang L, McGee S, Reiser J, Martin E, Nickerson DA, Hershberger RE
    Am. J. Hum. Genet.
    2011 Mar 11
    88(3):273-82.
  48. Mast cells, macrophages, and crown-like structures distinguish subcutaneous from visceral fat in mice.
    Altintas MM, Azad A, Nayer B, Contreras G, Zaias J, Faul C, Reiser J, Nayer A
    J. Lipid Res.
    2011 Mar
    52(3):480-8.
  49. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis.
    Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, Li J, Mattiazzi A, Ciancio G, Chen L, Zilleruelo G, Abitbol C, Chandar J, Seeherunvong W, Ricordi C, Ikehata M, Rastaldi MP, Reiser J, Burke GW
    Sci Transl Med
    2011 Jun 1
    3(85):85ra46.
  50. Minimal change disease as a modifiable podocyte paracrine disorder.
    Wei C, Reiser J
    Nephrol. Dial. Transplant.
    2011 Jun
    26(6):1776-7.
  51. TRPC channel modulation in podocytes-inching toward novel treatments for glomerular disease.
    El Hindi S, Reiser J
    Pediatr. Nephrol.
    2011 Jul
    26(7):1057-64.
  52. Filtering new facts about kidney disease.
    Reiser J
    Nat. Med.
    2011 Jan
    17(1):44-5.
  53. TRPC6 in podocytes: questions and commentary on the article by Jiang et al., 'Over-expressing transient receptor potential cation channel 6 in podocytes induces cytoskeleton rearrangement through increases of intracellular Ca21 and RhoA activation'.
    Kistler AD, Faul C, Reiser J
    Exp. Biol. Med. (Maywood)
    2011 Dec
    236(12):1361; author reply 1362-3.
  54. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.
    Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanchi SA, Yap HK, Saleem M, Zhang Q, Nikolic B, Chaudhuri A, Daftarian P, Salido E, Torres A, Salifu M, Sarwal MM, Schaefer F, Morath C, Schwenger V, Zeier M, Gupta V, Roth D, Rastaldi MP, Burke G, Ruiz P, Reiser J
    Nat. Med.
    2011 Aug
    17(8):952-60.
  55. Apoptosis, mastocytosis, and diminished adipocytokine gene expression accompany reduced epididymal fat mass in long-standing diet-induced obese mice.
    Altintas MM, Rossetti MA, Nayer B, Puig A, Zagallo P, Ortega LM, Johnson KB, McNamara G, Reiser J, Mendez AJ, Nayer A
    Lipids Health Dis
    2011
    10:198.
  56. Specialized roles for cysteine cathepsins in health and disease.
    Reiser J, Adair B, Reinheckel T
    J. Clin. Invest.
    2010 Oct
    120(10):3421-31.
  57. TRPC6 channels and their binding partners in podocytes: role in glomerular filtration and pathophysiology.
    Dryer SE, Reiser J
    Am. J. Physiol. Renal Physiol.
    2010 Oct
    299(4):F689-701.
  58. Direct dynamin-actin interactions regulate the actin cytoskeleton.
    Gu C, Yaddanapudi S, Weins A, Osborn T, Reiser J, Pollak M, Hartwig J, Sever S
    EMBO J.
    2010 Nov 3
    29(21):3593-606.
  59. Prkdc participates in mitochondrial genome maintenance and prevents Adriamycin-induced nephropathy in mice.
    Papeta N, Zheng Z, Schon EA, Brosel S, Altintas MM, Nasr SH, Reiser J, D'Agati VD, Gharavi AG
    J. Clin. Invest.
    2010 Nov
    120(11):4055-64.
  60. Enzymatic disease of the podocyte.
    Kistler AD, Peev V, Forst AL, El Hindi S, Altintas MM, Reiser J
    Pediatr. Nephrol.
    2010 Jun
    25(6):1017-23.
  61. Nephrin is expressed on the surface of insulin vesicles and facilitates glucose-stimulated insulin release.
    Fornoni A, Jeon J, Varona Santos J, Cobianchi L, Jauregui A, Inverardi L, Mandic SA, Bark C, Johnson K, McNamara G, Pileggi A, Molano RD, Reiser J, Tryggvason K, Kerjaschki D, Berggren PO, Mundel P, Ricordi C
    Diabetes
    2010 Jan
    59(1):190-9.
  62. Maximal 'CD80-uria' with minimal change.
    Kistler AD, Reiser J
    Kidney Int.
    2010 Aug
    78(3):236-8.
  63. Toward the development of podocyte-specific drugs.
    Reiser J, Gupta V, Kistler AD
    Kidney Int.
    2010 Apr
    77(8):662-8.
  64. Proteinuria: an enzymatic disease of the podocyte?
    Mundel P, Reiser J
    Kidney Int.
    2010 Apr
    77(7):571-80.
  65. Novel siRNA delivery system to target podocytes in vivo.
    Hauser PV, Pippin JW, Kaiser C, Krofft RD, Brinkkoetter PT, Hudkins KL, Kerjaschki D, Reiser J, Alpers CE, Shankland SJ
    PLoS ONE
    2010
    5(3):e9463.
  66. Establishment of protein delivery systems targeting podocytes.
    Chiang WC, Geel TM, Altintas MM, Sever S, Ruiters MH, Reiser J
    PLoS ONE
    2010
    5(7):e11837.
  67. Podocyte-specific overexpression of wild type or mutant trpc6 in mice is sufficient to cause glomerular disease.
    Krall P, Canales CP, Kairath P, Carmona-Mora P, Molina J, Carpio JD, Ruiz P, Mezzano SA, Li J, Wei C, Reiser J, Young JI, Walz K
    PLoS ONE
    2010
    5(9):e12859.
  68. Role of podocytes in lupus nephritis.
    Trivedi S, Zeier M, Reiser J
    Nephrol. Dial. Transplant.
    2009 Dec
    24(12):3607-12.
  69. A novel TRPC6 mutation that causes childhood FSGS.
    Heeringa SF, Möller CC, Du J, Yue L, Hinkes B, Chernin G, Vlangos CN, Hoyer PF, Reiser J, Hildebrandt F
    PLoS ONE
    2009
    4(11):e7771.